TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes
Brief Summary: The purpose of this study is to determine if a randomized trial of physical therapy for pelvic pain is feasible.


Options:
A: Arm Label: Alfuzosin; Type: EXPERIMENTAL; Interventions: Drug: Alfuzosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alfuzosin; Assigned to Arm(s): Alfuzosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
D: Arm Label: Silodosin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 4 mg | Arm Label: Silodosin 8 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin 8 mg; Assigned to Arm(s): Silodosin 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Silodosin 4 mg; Assigned to Arm(s): Silodosin 4 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes
Brief Summary: The purpose of this study is to determine if a randomized trial of physical therapy for pelvic pain is feasible.


Options:
A: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
B: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A
C: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Umbilical Cord Cleansing With Chlorhexidine on Neonatal Mortality and Omphalitis in Rural Sylhet District of Bangladesh
Brief Summary: A community based trial that seeks to address the effect of umbilical cord cleansing using 4.0% chlorhexidine cleansing solution


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CHX x 7 days | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: chx once | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dry cord care | Intervention Type: BEHAVIORAL; Name: chx once; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CHX x 7 days; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: dry cord care; Assigned to Arm(s): 3
B: Intervention Type: BEHAVIORAL; Name: Newborn skin cleansing with 0.25% chlorhexidine solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with soap and water solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with 4% chlorhexidine; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: Hand washing Soap | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Hand washing Soap; Assigned to Arm(s): B | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): C
D: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Umbilical Cord Cleansing With Chlorhexidine on Neonatal Mortality and Omphalitis in Rural Sylhet District of Bangladesh
Brief Summary: A community based trial that seeks to address the effect of umbilical cord cleansing using 4.0% chlorhexidine cleansing solution


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CHX x 7 days | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: chx once | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dry cord care | Intervention Type: BEHAVIORAL; Name: chx once; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CHX x 7 days; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: dry cord care; Assigned to Arm(s): 3
B: Intervention Type: BEHAVIORAL; Name: Newborn skin cleansing with 0.25% chlorhexidine solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with soap and water solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with 4% chlorhexidine; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: Hand washing Soap | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Hand washing Soap; Assigned to Arm(s): B | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): C
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine, Procedure: Birth canal wipe | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: sterile water external genital wipe | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Birth canal wipe; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: sterile water external genital wipe; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Active Observational Study of the Adoption and Transfer of Clinical Practice Guidelines Through Education, for Ventilator Associated Pneumonia (ABATE VAP Study)
Brief Summary: The purpose of this prospective, multicentre, time-series study is to develop, implement, refine, and evaluate a sustainable behaviour change strategy in the intensive care unit (ICU).


Options:
A: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
B: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy
C: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit
D: Arm Label: 1; Type: N/A; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma
Brief Summary: This is a placebo-controlled, randomized, multicenter Phase III study that will evaluate the safety and efficacy of bevacizumab, administered in combination with carboplatin with gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.


Options:
A: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
B: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo
C: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
D: Arm Label: avelumab; Type: EXPERIMENTAL; Interventions: Biological: avelumab | Arm Label: avelumab plus pegylated liposomal doxorubicin (PLD); Type: EXPERIMENTAL; Interventions: Biological: avelumab, Drug: PLD | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: BIOLOGICAL; Name: avelumab; Assigned to Arm(s): avelumab, avelumab plus pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD, avelumab plus pegylated liposomal doxorubicin (PLD)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma
Brief Summary: This is a placebo-controlled, randomized, multicenter Phase III study that will evaluate the safety and efficacy of bevacizumab, administered in combination with carboplatin with gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo
B: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo
C: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
D: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma
Brief Summary: This is a placebo-controlled, randomized, multicenter Phase III study that will evaluate the safety and efficacy of bevacizumab, administered in combination with carboplatin with gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.


Options:
A: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
B: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo
C: Arm Label: BIBF1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF1120 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BIBF1120; Assigned to Arm(s): BIBF1120 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency
Brief Summary: In this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone testosterone.

Specifically, we have studied the effects on:

* symptoms suggestive of low testosterone levels
* blood testosterone and other hormone levels
* bone mass
* muscle mass and fat mass
* muscle strength
* prostate
* lipids, hematocrit


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral testosterone undecanoate (Andriol) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral testosterone undecanoate (Andriol); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: Oral testosterone undecanoate; Type: EXPERIMENTAL; Interventions: Drug: Oral testosterone undecanoate | Arm Label: Transdermal testosterone gel (AndroGel); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal testosterone gel (AndroGel) | Intervention Type: DRUG; Name: Oral testosterone undecanoate; Assigned to Arm(s): Oral testosterone undecanoate | Intervention Type: DRUG; Name: Transdermal testosterone gel (AndroGel); Assigned to Arm(s): Transdermal testosterone gel (AndroGel)
C: Arm Label: Oral testosterone undecanoate (TU); Type: EXPERIMENTAL; Interventions: Drug: Oral testosterone undecanoate | Arm Label: topical testosterone gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: topical testosterone gel | Intervention Type: DRUG; Name: Oral testosterone undecanoate; Assigned to Arm(s): Oral testosterone undecanoate (TU) | Intervention Type: DRUG; Name: topical testosterone gel; Assigned to Arm(s): topical testosterone gel
D: Arm Label: AndroGel 1.62%; Type: ACTIVE_COMPARATOR; Interventions: Drug: AndroGel® | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AndroGel®; Assigned to Arm(s): AndroGel 1.62% | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury
Brief Summary: Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.


Options:
A: Intervention Type: DRUG; Name: HL 10; Assigned to Arm(s): N/A
B: Arm Label: AP301; Type: EXPERIMENTAL; Interventions: Drug: AP301 | Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Intervention Type: DRUG; Name: AP301; Assigned to Arm(s): AP301 | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): saline solution
C: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A
D: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D